• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Philips Volcano touts 5,000-patient iFR study

Philips Volcano touts 5,000-patient iFR study

April 1, 2016 By Fink Densford

PhilipsRoyal Philips (NYSE:PHG) said today it has enrolled more than 5,000 patients in 3 clinical studies examining its Volcano proprietary instant wave-free ratio pressure measurement technology against conventional fractional flow reserve measurements.

Both FFR and iFR measure differences in blood pressure through partially blocked coronary arteries to assess whether blockage is caused by a shortage of oxygen to the heart muscle, Philips said.

Both methods are performed with a guide wire-based pressure sensor inserted into the artery through the patient’s leg, but FFR requires an injection of a hyperemic agent to dilate the artery, Philips said. The iFR method synchronizes pressure measurements to a “wave-free” period in the patient’s heartbeat, the company said.

Philips said the combined 3 studies represent “1 of the largest intra-coronary physiolgoic data sets ever collected,” more than 2 times the size of the combined enrollment of the Defer, Fame and Fame 2 studies.

“The combination of these studies adds to the wealth of already published prospective physiology outcome data and may help expand the adoption of iFR, which is already used in over 3,000 cath labs worldwide. Additionally, the nearly 2,000 patients with ACS significantly add to the evidence on physiologic assessment in this type of condition, and may be able to help physicians determine the most appropriate treatment and improve patient care,” image guided therapy devices segment leader Andrew Tochterman

Of the 3 studies, the Define-Flair and iFR Swedeheart aim to assess differences in patient outcomes at 1 year when guided by both iFR and FFR.

The last trial, the Syntax II, aims to evaluate the relative treatment outcomes of hybrid iFR/FFR strategies in addition to intravascular ultrasound guidance to compare the clinical utility of percutaneous coronary interventions against bypass surgeries for 3-vessel coronary disease.

“We are all really excited about completing enrollment for the Define-Flair, iFR Swedeheart and Syntax II studies. Together, these three major clinical outcome studies will more than double the randomized published physiology data, and have the potential to re-shape revascularization guidelines and help physicians perform PCI procedures more likely to benefit their patients,” Define-Flair study chair and Syntax II steering committee chair Patrick Serruys said in prepared remarks.

Filed Under: Cardiovascular, Clinical Trials, Vascular Tagged With: Philips

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy